News

Photo

Roquette to Acquire Qualicaps

French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.

Photo

Roche Teams up with Alnylam for Antihypertensive Drug

Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.

Photo

Bayer Lowers its Targets for the Year 2023

Bayer adjusted its full-year outlook for 2023 downward, mainly due to a significant further decline in sales of glyphosate-based products. The group has thus joined the ranks of chemical companies that have cut their annual targets in recent days and weeks.

Photo

Zeta Acquires 20% Stake in CB Consultancy

Zeta, an Austrian engineering specialist for biopharmaceutical process plants, acquired a 20% share in Swiss company CB Consultancy. The transaction was completed by Jul. 14, 2023.

Photo

Gelest Breaks Ground on New Production Facility

Gelest, a Mitsubishi Chemical Group company, recently broke ground on its latest production facility. The new facility is 4,600 square meters and is located at Galest’s global headquarters in Morrisville, PA. Completion of the facility is expected by Sept. 2024. The new facility enhances Gelest’s production capabilities in various customer applications such as microelectronics, medical devices, and advanced thermal coatings.

Photo

EU Chemical Production on the Downward Slope

CEFIC, the European Chemical Industry Council, expects the EU27 chemical production to decline by about 8% in 2023 compared to the previous year, with no imminent recovery of chemical demand in Europe.

Photo

Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC

Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi XDC on the Hong Kong Stock Exchange. Upon completion of the proposed listing, Wuxi XDC will remain a consolidated subsidiary.

Photo

Thermo Fisher Scientific to Buy CorEvitas

US scientific services supplier Thermo Fisher Scientific has agreed to acquire CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash. The transaction, which is expected to be completed by the end of 2023, is subject to customary closing conditions, including regulatory approvals.

Photo

Solenis Acquires Diversey for $4.6 Billion

Solenis, a specialty chemicals manufacturer for water-intensive industries, has completed its acquisition of Diversey, a hygiene and cleaning products provider, in an all-cash transaction valued at ~ $4.6 billion.

Photo

Avantium and SCGC Partner on CO2-based Polymers

Avantium, a technology provider in renewable chemistry, has agreed to partner with SCG Chemicals (SCGC), an integrated chemical player and innovator in Asia, to further develop CO2-based polymers and to scale-up to a pilot plant with an indicative annual capacity of 10 t.

Photo

BASF and Yara Clean Ammonia to Study US Project

BASF and Yara Clean Ammonia (YCA), a unit of Norwegian fertilizer producer Yara, have teamed up on a joint study to develop and build a world-scale low-carbon blue ammonia production facility with carbon capture in the US Gulf Coast region.

Photo

AstraZeneca and Daiichi Sankyo's Lung Cancer Drug Shows Promise, Shares Fall

Results from AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan clinical trials were released this week. The antibody drug, also known as Dato-DXd, was developed in partnership between the two companies and aims to help patients with the most common lung cancer live longer without worsening their condition when compared to standard treatments. However, the announcement fell short of expectations, leading to a decline in AstraZeneca's shares. 

Photo

Abcam Attracts Interest from US Life Sciences Giants

Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.

Photo

Solvay in $393 Million PFAS Deal with New Jersey

Belgian chemical major Solvay has reached a $393 million deal with the US state of New Jersey to remedy contamination from poly- and per-fluorinated alkyl substances (PFAS) – also known as “forever chemicals – caused by its subsidiary Solvay Specialty Polymers.

Photo

Arkema Takes Majority Stake in PI Advanced Materials

French specialty chemicals company Arkema plans to acquire the 54% majority stake held by Glenwood Private Equity in South Korea-listed PI Advanced Materials (PIAM) for €728 million and fully consolidate the holding. The remaining 46% of equity will continue to be listed in South Korea.

Photo

Germany’s Merck Expanding Reagents in China

As part of an agreement with China’s Nantong Economic and Technological Development Area (NETDA), Germany’s Merck said it plans to spend €70 million to expand production capacity for highly-purified reagents at its site in the Chinese city of the same name, a major transportation hub in the Yangtze River Delta region.

12798 more News

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.